Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
Background and objective To evaluate the clinical efficacy and the security of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD. Methods Fifteen patients with advanced non-small cell lung cancer and COPD were treated with erlotinib 150 mg/d, and then t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-12-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.14&path[]=1238 |
| Summary: | Background and objective To evaluate the clinical efficacy and the security of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer and COPD. Methods Fifteen patients with advanced non-small cell lung cancer and COPD were treated with erlotinib 150 mg/d, and then the adverse reactions and clinical effects were recorded. Results The effective rate was 20%. We analyzed the effective rate of stage III and IV, and there were no significant difference between the two (P=0.569). KPS was increased in 40% patients. Mild or moderate rash, diarrhea, nausea and vomiting were the main adverse reactions. Conclusion For elderly patients with advanced non-small cell lung cancer and COPD, the use of erlotinib might achieve better security and effectiveness. |
|---|---|
| ISSN: | 1009-3419 1999-6187 |